Transgene finds promise in NSCLC immunotherapy data
By Mari Serebrov
Friday, January 10, 2014
Transgene SA was riding high Thursday after releasing top-line preliminary data from a Phase IIb/III study of TG4010, an immunotherapy being developed for non-small-cell lung cancer (NSCLC).
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.